### Fiscal Year 2021 Alcohol and Substance Abuse Disorder Research Program (ASADRP)

#### Reference Table of Award Mechanisms and Submission Requirements

<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Consortium Award      | Independent intramural (DOD) and extramural Investigators at all academic levels (or equivalent). | • Supports a Consortium to identify promising compounds; conduct proof-of-principle basic research and conduct human proof-of-concept trials with promising compounds to address effective treatments for Alcohol and Substance Use Disorders, to include reducing the overall number of opioid-related overdose death.  
  • The Consortium will consist of a single management core as well as basic research and clinical trial sites. | • The maximum period of performance is 5 years.  
  • The CDMRP expects to allocate FY21-23 funding, if appropriated, to fund approximately one ASADRP Consortium Award.  
  • The ASADRP Consortium will be funded initially with allocations from the FY21 ASADRP congressional appropriation ($3.525M).  
  • The maximum allowable total costs (direct and indirect) for the entire period of performance are $10.575M (initial period of performance plus 2 options).  
  • Two additional options, to be included in the application, may be funded from allocations from the FY22 and FY23 congressional appropriation (up to $3.525M each year) subject to Programmatic Panel review, approval of the Grants Officer, and receipt of future congressional appropriations. | Pre-Application (Letter of Intent):  
  August 18, 2021  
  5:00 p.m. Eastern time (ET)  
  Application:  
  September 8, 2021  
  11:59 p.m. ET |

**Go to:**  
- [Program Announcement](#)  
- [General Application Instructions](#)  

**Grants.gov Funding Opportunity Number:**  
W81XWH-21-ASADRP-CA